Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Wesley Jessen VisionCare

This article was originally published in The Gray Sheet

Executive Summary

Wesley Jessen VisionCare: Nets approximately $11.3 mil. from secondary offering of 4 mil. shares at $23.50 each, including 500,000 shares offered by the company and 3.5 mil. by selling shareholders, the firm states. The Des Plaines, Illinois-based specialty soft contact lens maker, which went public in February ("The Gray Sheet" March 3, p. 16), plans to use the proceeds to reduce indebtedness. Most of the shareholder stock sold in the offering was owned by Bain Capital; Bain continues to hold just over 50% of the company, down from 77.4% following the IPO, the firm states. Underwriters for the offering include Alex. Brown & Sons, Merrill Lynch, Bear Stearns, and Salomon Brothers...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel